Physician profile
Wanda Marelis
NPI 1538789003
$3,086.74
in general payments reported to CMS, 2019-2025
15 companies · $1,675 in 2025
The $1,675 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $270 · 2023: $193 · 2024: $949 · 2025: $1,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,726 · Education: $90.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,726.09 |
| Education | $90.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,199.74 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $275.49 | 2024 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $269.95 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $261.38 | 2024-2025 | Rexulti |
| Corium, LLC | $143.39 | 2022-2023 | Azstarys |
| Abbvie INC. | $136.78 | 2025 | |
| Axsome Therapeutics, INC. | $121.85 | 2024 | Auvelity |
| Lundbeck LLC | $121.80 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $115.64 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $112.76 | 2024-2025 | Austedo Xr, Austedo Xr |
| Alkermes, INC. | $106.22 | 2024 | Aristada, Aristada Initio |
| Vanda Pharmaceuticals INC. | $101.86 | 2025 | Fanapt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $84.01 | 2025 | Rexulti, Rejoyn |
| Bayer Healthcare Pharmaceuticals INC. | $21.90 | 2024 | |
| Coopersurgical, INC. | $13.97 | 2024 | Paragard T 380a |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wanda Marelis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.